Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection
| Autor: | Shuhei Nishiguchi, Kristi L. Berger, Atsushi Taniguchi, Jerry O. Stern, Keiko Suzaki, Joseph Scherer, Yasuhisa Urano, Masao Omata, Anne-Marie Quinson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Hepatitis C virus 030106 microbiology medicine.disease_cause Gastroenterology Virus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pegylated interferon Internal medicine Genotype medicine Adverse effect Hepatology business.industry Ribavirin Virology Discontinuation Infectious Diseases chemistry Faldaprevir 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Hepatology Research. 47:E142-E151 |
| ISSN: | 1386-6346 |
| DOI: | 10.1111/hepr.12741 |
| Popis: | AIM We evaluated the safety and efficacy of the hepatitis C virus (HCV) NS3/4A A protease inhibitor faldaprevir plus pegylated interferon α-2b and ribavirin (PegIFNα-2b/RBV) in Japanese patients with HCV genotype-1 infection. METHODS Treatment-naive patients were randomized (1:1) to faldaprevir 120 mg q.d. for 12 or 24 weeks (response-guided therapy [RGT], n = 44), or faldaprevir 240 mg q.d. for 12 weeks (n = 43), each combined with PegIFNα-2b/RBV for 24 or 48 weeks (RGT). Response-guided therapy was based on early treatment success (HCV RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text